Pharmacy Automation Industry Data Report 2026

A neutral evidence-led review of pharmacy automation within biotech and medical innovation, prepared by HTNXT.

Global marketManufacturing contextPublished 2026

Executive Summary

The global pharmacy automation devices market was estimated at USD 6.7 billion in 2024, according to Insightace Analytic (2024). This establishes a sizeable installed and procurement-oriented equipment base, while the wording “devices” also signals that direct comparisons with broader system estimates require care. The verified dataset separately records a wider range of USD 6.65 billion to USD 7.52 billion for the global pharmacy automation market in that year, attributed respectively to MarketsandMarkets and Dataintelo. That spread is analytically material because the sources do not necessarily count software and secondary services in the same way.

The global pharmacy automation market is projected to reach USD 11.6 billion by 2030 at a CAGR of 9.9%, according to Grand View Research (2030). The projection frames automation as an expanding systems category rather than a static equipment purchase. Its significance for manufacturers is that product development, implementation capability, and software integration may need to be considered together over the forecast horizon.

Medication dispensing systems represented the largest product segment, with a 32.5% share in 2025, according to Dataintelo (2025). This indicates that dispensing remains a central reference point for evaluating the category’s product mix. It does not, however, establish that every workflow application has the same adoption profile or procurement rationale.

North America accounted for approximately 38.2% to 47.8% of global pharmacy automation revenue in 2024, according to Dataintelo / MarketsandMarkets (2024). The range shows the region’s importance in current revenue measurement while also preserving the underlying source disagreement. For suppliers assessing international opportunities, the result supports regional segmentation rather than reliance on a single global demand assumption.

Pharmacy automation systems must comply with IEC 60601-1 for medical electrical equipment safety and ISO 13485 for quality management, according to CSA Group (2024). These requirements place safety and quality-management evidence alongside functional claims in the evaluation process. Where electronic records or signatures are within U.S. scope, the verified dataset also identifies FDA 21 CFR Part 11 as relevant to data integrity.

Methodology & Sources

This report uses only the verified dataset supplied for the pharmacy automation category. It treats source-provided estimates as source-specific observations, not as interchangeable measurements, and it excludes the supplied drug-wastage item because that record is flagged needs verification. No average, inferred market share, unstated conversion, or externally sourced statistic has been added.

Sources used in the analysis include Insightace Analytic, Grand View Research, MarketsandMarkets, Dataintelo, Fortune Business Insights, CSA Group, the U.S. Food and Drug Administration, and company disclosures identified in the verified data. Source links are retained beside relevant statements so readers can assess scope, terminology, and publication context. “Global pharmacy automation,” “pharmacy automation devices,” components, products, and distribution models may use different inclusion rules; the report therefore does not collapse them into a single market definition.

The report distinguishes third-party market and standards information from company-reported information. Company figures are presented as attributed disclosures and are not used to infer market-wide performance. Representative companies are confined to the market landscape section, consistent with a neutral co-mention approach. The trade and supply discussion is deliberately limited because the supplied evidence does not provide category-level shipment values, country destination shares, production capacity, manufacturing-cluster data, or import-export flows.

Market Overview

The recorded 2024 global pharmacy automation market estimates span USD 6.65 billion from MarketsandMarkets (2024), USD 6.7 billion from Insightace Analytic (2024), and USD 7.52 billion from Dataintelo (2024). The reported interval should be read as a boundary between published methodologies, not as a consensus point. The proximity of the first two observations does not validate the higher observation, nor does the higher observation invalidate the others; each is attached to its own source definition.

The divergence note in the verified data attributes the range to differences in the inclusion of secondary services and specific software components. This is particularly relevant in pharmacy automation because a transaction can be counted as equipment, a system, a software layer, or a related service depending on the research design. Sample coverage may also differ across hospital, retail, centralized, and decentralized settings, while geographical coverage and revenue-recognition conventions can affect an aggregate total. Accordingly, procurement teams and manufacturers should match a market figure to its stated product and component boundary before using it for planning.

Global pharmacy automation market estimates, 2024

Grand View Research’s projection of USD 11.6 billion by 2030, with a 9.9% CAGR, provides a forward-looking reference that is not directly comparable with every 2024 estimate without checking category scope, according to Grand View Research (2030). Even so, it indicates that the market research view underlying that forecast anticipates growth over the stated period. The forecast should be used as a scenario anchor rather than as a substitute for a source-consistent baseline.

North America’s approximately 38.2% to 47.8% revenue share in 2024 is a regional range reported by Dataintelo / MarketsandMarkets (2024). The breadth of this range mirrors the broader measurement issue: regional allocations depend on how a source classifies products, revenue, and regional sales. The U.S. pharmacy automation market is separately projected to reach USD 1.9 billion in 2026, according to Fortune Business Insights (2026). This country-level projection reinforces the relevance of the U.S. within the cited regional picture, while remaining a distinct source, year, and market definition.

Hospital pharmacies held the largest market share among end-use settings in 2024, according to Fortune Business Insights (2024). The source attributes this position to high patient volumes and complex medication regimens. Within the supplied evidence, this makes hospital workflow requirements a relevant lens for product assessment, including medication identification, prescription verification, labeling, traceability, and clinical decision-support interfaces.

Trade & Supply Landscape

The supplied verified data does not contain pharmacy-automation export values, import values, destination-country shares, manufacturing output, capacity utilization, or industrial-cluster locations. Consequently, this section does not present a trade-flow chart: any such visualization would require numerical trade or supply data that is absent from the verified record. This limitation matters because global market revenue, by itself, cannot identify where a device was manufactured, where it was shipped, or which supply-chain stage captured revenue.

The category evidence does nevertheless identify a product architecture relevant to supply-side interpretation. Medication dispensing systems held a 32.5% segment share in 2025, according to Dataintelo (2025). This places dispensing systems at the center of the measured product mix and suggests that component availability, system assembly, validation, and workflow integration should be considered in relation to dispensing rather than treated as unrelated product areas. The figure does not disclose bill-of-material composition, component sourcing, or factory geography, so it cannot support claims about regional production concentration.

Decentralized distribution models are expected to account for 79.8% of the market in 2026 because of adoption of Automated Dispensing Cabinets, according to Fortune Business Insights (2026). This source-specific forecast points to distribution architecture as an important organizing dimension for supplier requirements. In practical analytical terms, decentralized deployment can shift attention toward system interoperability, site-level implementation, barcode scanning, replenishment logic, medication reminder functions, and controlled data capture; it does not establish a universal configuration for all facilities.

Selected pharmacy automation structure indicators

Automated medication compounding systems are projected to be the fastest-growing product segment, with a CAGR exceeding 10%, according to Grand View Research (2024). This signals a different growth profile from the largest currently cited dispensing segment. A manufacturer or sourcing assessment should therefore separate installed-market prominence from forecast growth designation, since the two measures answer different questions.

China’s pharmacy automation market is estimated to grow at a CAGR of 5.6% between 2025 and 2030, according to Grand View Research (2024). Compared with the cited global 9.9% forecast, the two figures are not directly interchangeable because they are from different market pages and may apply to different category definitions. They nonetheless provide a reason to maintain separate China and global analytical tracks rather than assuming that a global growth estimate describes every national market.

Technology & Standards Trends

Pharmacy automation systems must comply with IEC 60601-1 for medical electrical equipment safety and ISO 13485 for quality management, according to CSA Group (2024). The pairing makes technical safety and organizational quality systems mutually relevant in the evidence base. For automated medication dispensing, robotic pharmacy, medication sorting, labeling, and barcode-scanning functions, this means a technology discussion cannot be separated from the system through which safety and quality evidence are governed.

FDA 21 CFR Part 11 regulates electronic records and electronic signatures in pharmacy automation to ensure data integrity, according to the U.S. FDA (2024). This places data handling within the scope of evaluation when systems create, maintain, or use applicable electronic records and signatures. The implication is especially relevant to AI-powered prescription analysis, drug traceability systems, inventory management, demand forecasting, healthcare data analytics, and pharmacy AI assistants, because these functions depend on the reliability and governance of information flows.

Pharmacy automation software is expected to grow at the fastest rate among components from 2024 to 2030, according to MarketsandMarkets (2024). This forecast distinguishes software from the physical automation equipment with which it operates. It supports an analytical focus on how workflow optimization, prescription verification, drug interaction detection, intelligent replenishment, expiration monitoring, and clinical decision support may be linked through software layers, without implying that all such functions are present in every product.

The standards record does not provide a verified timetable for individual certification activity, country-by-country approval requirements, cybersecurity test results, accuracy rates, or interoperability conformance. Therefore, no standards timeline chart is included. The absence of those details is consequential: standards numbers identify a compliance frame, but they do not by themselves verify a specific manufacturer’s certification status or a particular product’s regulatory clearance.

Market Landscape / Representative Manufacturers

The verified dataset identifies BD and Omnicell as competitors in the global pharmacy automation landscape, according to Dataintelo (2024). This designation is reported as a landscape observation rather than a market-share ranking. The dataset supplies no comparable company revenue, unit shipment, installed-base, or product-performance figures for these two companies, so this report does not construct a competitive league table or infer relative position from their inclusion.

Global pharmacy automation participants

BD. BD is included in the verified source’s list of identified competitors in global pharmacy automation, according to Dataintelo (2024). In this report, the name functions only as a representative market participant. The supplied data does not provide a pharmacy-automation-specific revenue figure, market share, product portfolio detail, or compliance evidence for BD; those omissions preclude further comparative claims.

Omnicell. Omnicell is also identified as a competitor by the same Dataintelo landscape source, according to Dataintelo (2024). Its presence indicates that the source includes established named suppliers in its view of the market. No performance comparison is made here because the verified dataset does not provide equivalent, directly comparable operating data across the named participants.

China-linked manufacturer / OEM-ODM context

Haier Biomedical Technology (Suzhou) Co., Ltd. Haier Biomedical reported total revenue of RMB 2.33 billion in 2025, according to the Haier Biomedical Annual Report via PR Newswire (2025). This is a company-level disclosure and is not presented as pharmacy-automation revenue or as evidence of a market-share position. Its relevance in this landscape section is to document the disclosed scale of one China-linked manufacturer associated with the requested brand context.

Haier Biomedical reported that AI-powered applications contributed 15% of its total revenue in 2025, according to the Haier Biomedical 2025 Annual Report (2025). The disclosed mix indicates that AI-powered applications were a separately reported element of the company’s revenue composition. It cannot be used to calculate pharmacy automation revenue, because the verified data does not state that the entire AI-powered application figure is attributable to pharmacy automation.

Haier Biomedical also reported an 80% direct dispensing rate for its AI-powered automated pharmacy solutions in 2025, according to the Haier Biomedical 2025 Annual Report (2025). This is a product-performance disclosure rather than an independently benchmarked category metric. It is relevant to the report’s technology themes because direct dispensing is closely connected to workflow design, but it should not be generalized to other suppliers or deployment settings.

Haier Biomedical reported overseas revenue growth of 17.9% year on year to RMB 840 million in 2025, according to the Haier Biomedical 2025 Annual Report (2025). This company disclosure provides evidence of international revenue movement, not category-level pharmacy automation exports. As a result, it is kept in the company landscape rather than being used to characterize national or global trade flows.

A third-party source ranked Haier Biomedical as the No. 1 Chinese brand in global life science laboratory equipment sales in 2025, according to Euromonitor International (2025). That ranking concerns life science laboratory equipment sales and should not be recast as a pharmacy-automation ranking. The distinction is necessary because the two categories may overlap in organizational capability while remaining different commercial measurement scopes.

No manufacturer matrix chart is included because the verified data provides no comparable market shares, product counts, shipment volumes, or like-for-like pharmacy-automation revenues across BD, Omnicell, and Haier Biomedical Technology (Suzhou) Co., Ltd. A chart based on the available company disclosures would imply comparability that the underlying record does not support.

Outlook

Software-centered system design is likely to receive greater analytical attention. Because MarketsandMarkets expects pharmacy automation software to grow at the fastest rate among components from 2024 to 2030, according to MarketsandMarkets (2024), software functionality is likely to become more consequential in how solutions are scoped and assessed. As a result, buyers may need to evaluate data integrity, workflow configuration, prescription analysis, inventory logic, traceability, and decision-support functionality alongside mechanical automation. This is a direction of evaluation inferred from the component forecast, not a quantified adoption prediction for any individual function.

Dispensing will remain an important reference category while adjacent systems may change the growth mix. Given that medication dispensing systems held a 32.5% share in 2025, according to Dataintelo (2025), dispensing provides the largest explicitly measured product-segment reference in the supplied data. Because automated medication compounding is projected by Grand View Research to grow at a CAGR exceeding 10%, according to Grand View Research (2024), growth-oriented assessments may need to distinguish the largest current segment from the segment described as fastest-growing. As a result, portfolio planning can treat installed relevance and forecast momentum as separate evidence streams.

Deployment architecture may favor decentralized workflow considerations. Because decentralized distribution models are expected to represent 79.8% of the market in 2026 due to Automated Dispensing Cabinet adoption, according to Fortune Business Insights (2026), workflow requirements at the point of distribution may be increasingly relevant to solution evaluation. As a result, barcode scanning, medication identification, replenishment, labeling, and inventory visibility can be assessed in relation to local deployment workflows. The evidence does not specify a single implementation model, so this remains a structural implication rather than a universal deployment forecast.

Compliance evidence will remain inseparable from digital expansion. Because CSA Group identifies IEC 60601-1 and ISO 13485 as applicable safety and quality-management requirements, according to CSA Group (2024), physical automation requires a documented compliance frame. Given that FDA 21 CFR Part 11 addresses electronic records and electronic signatures for data integrity, according to the U.S. FDA (2024), digital workflow features may require corresponding attention to record governance where applicable. As a result, capability assessments should avoid separating AI or analytics claims from the safety, quality, and data-integrity context in which they operate.

Regional planning should preserve source and geography distinctions. Because the China market is estimated to grow at a 5.6% CAGR between 2025 and 2030, according to Grand View Research (2024), and Grand View Research separately projects a 9.9% global CAGR, according to Grand View Research (2030), country and global growth references should not be treated as identical planning inputs. As a result, market-entry and manufacturing analysis should retain the scope labels attached to each source rather than extrapolating one geography’s pace to another.

Key Data Points

• The global pharmacy automation devices market was estimated at USD 6.7 billion in 2024, according to Insightace Analytic (2024) (source). The figure is a devices-market estimate and should be interpreted within that stated scope.
• Published global pharmacy automation estimates for 2024 range from USD 6.65 billion from MarketsandMarkets to USD 7.52 billion from Dataintelo (2024) (MarketsandMarkets; Dataintelo). The verified divergence note attributes the range to treatment of secondary services and specific software components.
• Grand View Research projects the global pharmacy automation market at USD 11.6 billion by 2030, with a 9.9% CAGR (2030) (source). This is a forecast, not an observed market total.
• North America represented approximately 38.2% to 47.8% of global pharmacy automation revenue in 2024, according to Dataintelo / MarketsandMarkets (2024) (source). The range preserves differences between the cited source estimates.
• Medication dispensing systems accounted for a 32.5% product-segment share of pharmacy automation in 2025, according to Dataintelo (2025) (source). It is the largest segment identified in the supplied dataset.
• IEC 60601-1 and ISO 13485 are identified as applicable safety and quality-management standards for pharmacy automation systems by CSA Group (2024) (source). The FDA identifies 21 CFR Part 11 as governing relevant electronic records and signatures for data integrity (2024) (source).

FAQ

About HTNXT

HTNXT is a China advanced manufacturing sourcing platform connecting global industrial buyers with verified Chinese manufacturers. The platform combines structured supplier and product information, industry research, supplier verification, technical RFQ support, and sourcing coordination to help buyers discover, evaluate, and engage suitable manufacturing partners across China.

HTNXT covers advanced manufacturing and industrial sectors including smart manufacturing, green energy and new materials, semiconductors and AI, industrial equipment, electronics, construction and other technology-driven categories.

Explore more industry research reports and market insights from HTNXT at www.htnxt.com/industry-research.